The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
Introduction Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied. Aims We aime...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2017-07, Vol.77 (11), p.1187-1197 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1197 |
|---|---|
| container_issue | 11 |
| container_start_page | 1187 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 77 |
| creator | Sahebkar, Amirhossein Serban, Maria-Corina Penson, Peter Gurban, Camelia Ursoniu, Sorin Toth, Peter P. Jones, Steven R. Lippi, Giuseppe Kotani, Kazuhiko Kostner, Karam Rizzo, Manfredi Rysz, Jacek Banach, Maciej |
| description | Introduction
Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied.
Aims
We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies.
Methods
This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate.
Results
Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD −0.41, 95% confidence interval −0.68 to −0.14,
p
= 0.003). This effect was robust in the sensitivity analysis.
Conclusions
Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results. |
| doi_str_mv | 10.1007/s40265-017-0767-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5501893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1973330974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-c0b2d3eb729dc2d8ae4fa78cdf4664c1114c16c6d0d66e5a25e2b3400da916903</originalsourceid><addsrcrecordid>eNp1kU1vFDEMhiNERZfCD-CCInFpD6HOfCQTDkjVqnxIW4FgOUfZjKdNNZNsk9nS_fdkNKVqkbjYsvz4jZ2XkDcc3nMAeZoqKETNgEsGUkhWPSMLzqViXNXwnCwAeMGEEPKQvEzpeipVrV6Qw6KpZVmVYkFwfYX0vOvQjomGjq7NEO5ch54GT7_3Jg2Grtw2bGMY0fljc0KXwVv0YzSjCz59oD_3acQhV5b-wFuHv6nxLb3A0bAzb_p9cukVOehMn_D1fT4ivz6dr5df2Orb56_LsxWzlYSRWdgUbYkbWajWFm1jsOqMbGzbVUJUlnOeg7CihVYIrE1RY7EpK4DWKC4UlEfk46y73W0GbOc1e72NbjBxr4Nx-mnHuyt9GW51XQNvVJkFju8FYrjZYRr14JLFvjcewy5priD_XKN4ndF3_6DXYRfzwRMly7IEJatM8ZmyMaQUsXtYhoOeTNSziTqbqCcT9TTz9vEVDxN_XctAMQMpt_wlxkdP_1f1D8plqHY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1973330974</pqid></control><display><type>article</type><title>The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Sahebkar, Amirhossein ; Serban, Maria-Corina ; Penson, Peter ; Gurban, Camelia ; Ursoniu, Sorin ; Toth, Peter P. ; Jones, Steven R. ; Lippi, Giuseppe ; Kotani, Kazuhiko ; Kostner, Karam ; Rizzo, Manfredi ; Rysz, Jacek ; Banach, Maciej</creator><creatorcontrib>Sahebkar, Amirhossein ; Serban, Maria-Corina ; Penson, Peter ; Gurban, Camelia ; Ursoniu, Sorin ; Toth, Peter P. ; Jones, Steven R. ; Lippi, Giuseppe ; Kotani, Kazuhiko ; Kostner, Karam ; Rizzo, Manfredi ; Rysz, Jacek ; Banach, Maciej ; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group ; for the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><description>Introduction
Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied.
Aims
We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies.
Methods
This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate.
Results
Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD −0.41, 95% confidence interval −0.68 to −0.14,
p
= 0.003). This effect was robust in the sensitivity analysis.
Conclusions
Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-017-0767-4</identifier><identifier>PMID: 28573436</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Cardiovascular disease ; Cell Line, Tumor ; Cholesterol ; Confidence intervals ; Disease prevention ; Estrogens ; Female ; Humans ; Internal Medicine ; Lipids ; Lipoprotein(a) - blood ; Medicine ; Medicine & Public Health ; Meta-analysis ; Pharmacology/Toxicology ; Pharmacotherapy ; Randomized Controlled Trials as Topic ; Reduction ; Selective Estrogen Receptor Modulators ; Sensitivity analysis ; Statistical analysis ; Statistical significance ; Studies ; Systematic Review ; Tamoxifen ; Tamoxifen - pharmacology ; Tamoxifen - therapeutic use ; Triglycerides ; Womens health</subject><ispartof>Drugs (New York, N.Y.), 2017-07, Vol.77 (11), p.1187-1197</ispartof><rights>The Author(s) 2017</rights><rights>Copyright Springer Science & Business Media Jul 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-c0b2d3eb729dc2d8ae4fa78cdf4664c1114c16c6d0d66e5a25e2b3400da916903</citedby><cites>FETCH-LOGICAL-c470t-c0b2d3eb729dc2d8ae4fa78cdf4664c1114c16c6d0d66e5a25e2b3400da916903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-017-0767-4$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-017-0767-4$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28573436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><creatorcontrib>Serban, Maria-Corina</creatorcontrib><creatorcontrib>Penson, Peter</creatorcontrib><creatorcontrib>Gurban, Camelia</creatorcontrib><creatorcontrib>Ursoniu, Sorin</creatorcontrib><creatorcontrib>Toth, Peter P.</creatorcontrib><creatorcontrib>Jones, Steven R.</creatorcontrib><creatorcontrib>Lippi, Giuseppe</creatorcontrib><creatorcontrib>Kotani, Kazuhiko</creatorcontrib><creatorcontrib>Kostner, Karam</creatorcontrib><creatorcontrib>Rizzo, Manfredi</creatorcontrib><creatorcontrib>Rysz, Jacek</creatorcontrib><creatorcontrib>Banach, Maciej</creatorcontrib><creatorcontrib>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><creatorcontrib>for the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><title>The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Introduction
Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied.
Aims
We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies.
Methods
This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate.
Results
Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD −0.41, 95% confidence interval −0.68 to −0.14,
p
= 0.003). This effect was robust in the sensitivity analysis.
Conclusions
Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cardiovascular disease</subject><subject>Cell Line, Tumor</subject><subject>Cholesterol</subject><subject>Confidence intervals</subject><subject>Disease prevention</subject><subject>Estrogens</subject><subject>Female</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lipids</subject><subject>Lipoprotein(a) - blood</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Reduction</subject><subject>Selective Estrogen Receptor Modulators</subject><subject>Sensitivity analysis</subject><subject>Statistical analysis</subject><subject>Statistical significance</subject><subject>Studies</subject><subject>Systematic Review</subject><subject>Tamoxifen</subject><subject>Tamoxifen - pharmacology</subject><subject>Tamoxifen - therapeutic use</subject><subject>Triglycerides</subject><subject>Womens health</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU1vFDEMhiNERZfCD-CCInFpD6HOfCQTDkjVqnxIW4FgOUfZjKdNNZNsk9nS_fdkNKVqkbjYsvz4jZ2XkDcc3nMAeZoqKETNgEsGUkhWPSMLzqViXNXwnCwAeMGEEPKQvEzpeipVrV6Qw6KpZVmVYkFwfYX0vOvQjomGjq7NEO5ch54GT7_3Jg2Grtw2bGMY0fljc0KXwVv0YzSjCz59oD_3acQhV5b-wFuHv6nxLb3A0bAzb_p9cukVOehMn_D1fT4ivz6dr5df2Orb56_LsxWzlYSRWdgUbYkbWajWFm1jsOqMbGzbVUJUlnOeg7CihVYIrE1RY7EpK4DWKC4UlEfk46y73W0GbOc1e72NbjBxr4Nx-mnHuyt9GW51XQNvVJkFju8FYrjZYRr14JLFvjcewy5priD_XKN4ndF3_6DXYRfzwRMly7IEJatM8ZmyMaQUsXtYhoOeTNSziTqbqCcT9TTz9vEVDxN_XctAMQMpt_wlxkdP_1f1D8plqHY</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Sahebkar, Amirhossein</creator><creator>Serban, Maria-Corina</creator><creator>Penson, Peter</creator><creator>Gurban, Camelia</creator><creator>Ursoniu, Sorin</creator><creator>Toth, Peter P.</creator><creator>Jones, Steven R.</creator><creator>Lippi, Giuseppe</creator><creator>Kotani, Kazuhiko</creator><creator>Kostner, Karam</creator><creator>Rizzo, Manfredi</creator><creator>Rysz, Jacek</creator><creator>Banach, Maciej</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170701</creationdate><title>The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis</title><author>Sahebkar, Amirhossein ; Serban, Maria-Corina ; Penson, Peter ; Gurban, Camelia ; Ursoniu, Sorin ; Toth, Peter P. ; Jones, Steven R. ; Lippi, Giuseppe ; Kotani, Kazuhiko ; Kostner, Karam ; Rizzo, Manfredi ; Rysz, Jacek ; Banach, Maciej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-c0b2d3eb729dc2d8ae4fa78cdf4664c1114c16c6d0d66e5a25e2b3400da916903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cardiovascular disease</topic><topic>Cell Line, Tumor</topic><topic>Cholesterol</topic><topic>Confidence intervals</topic><topic>Disease prevention</topic><topic>Estrogens</topic><topic>Female</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lipids</topic><topic>Lipoprotein(a) - blood</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Reduction</topic><topic>Selective Estrogen Receptor Modulators</topic><topic>Sensitivity analysis</topic><topic>Statistical analysis</topic><topic>Statistical significance</topic><topic>Studies</topic><topic>Systematic Review</topic><topic>Tamoxifen</topic><topic>Tamoxifen - pharmacology</topic><topic>Tamoxifen - therapeutic use</topic><topic>Triglycerides</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><creatorcontrib>Serban, Maria-Corina</creatorcontrib><creatorcontrib>Penson, Peter</creatorcontrib><creatorcontrib>Gurban, Camelia</creatorcontrib><creatorcontrib>Ursoniu, Sorin</creatorcontrib><creatorcontrib>Toth, Peter P.</creatorcontrib><creatorcontrib>Jones, Steven R.</creatorcontrib><creatorcontrib>Lippi, Giuseppe</creatorcontrib><creatorcontrib>Kotani, Kazuhiko</creatorcontrib><creatorcontrib>Kostner, Karam</creatorcontrib><creatorcontrib>Rizzo, Manfredi</creatorcontrib><creatorcontrib>Rysz, Jacek</creatorcontrib><creatorcontrib>Banach, Maciej</creatorcontrib><creatorcontrib>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><creatorcontrib>for the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahebkar, Amirhossein</au><au>Serban, Maria-Corina</au><au>Penson, Peter</au><au>Gurban, Camelia</au><au>Ursoniu, Sorin</au><au>Toth, Peter P.</au><au>Jones, Steven R.</au><au>Lippi, Giuseppe</au><au>Kotani, Kazuhiko</au><au>Kostner, Karam</au><au>Rizzo, Manfredi</au><au>Rysz, Jacek</au><au>Banach, Maciej</au><aucorp>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</aucorp><aucorp>for the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>77</volume><issue>11</issue><spage>1187</spage><epage>1197</epage><pages>1187-1197</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Introduction
Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied.
Aims
We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies.
Methods
This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate.
Results
Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD −0.41, 95% confidence interval −0.68 to −0.14,
p
= 0.003). This effect was robust in the sensitivity analysis.
Conclusions
Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>28573436</pmid><doi>10.1007/s40265-017-0767-4</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2017-07, Vol.77 (11), p.1187-1197 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5501893 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cardiovascular disease Cell Line, Tumor Cholesterol Confidence intervals Disease prevention Estrogens Female Humans Internal Medicine Lipids Lipoprotein(a) - blood Medicine Medicine & Public Health Meta-analysis Pharmacology/Toxicology Pharmacotherapy Randomized Controlled Trials as Topic Reduction Selective Estrogen Receptor Modulators Sensitivity analysis Statistical analysis Statistical significance Studies Systematic Review Tamoxifen Tamoxifen - pharmacology Tamoxifen - therapeutic use Triglycerides Womens health |
| title | The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A04%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effects%20of%20Tamoxifen%20on%20Plasma%20Lipoprotein(a)%20Concentrations:%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Sahebkar,%20Amirhossein&rft.aucorp=Lipid%20and%20Blood%20Pressure%20Meta-analysis%20Collaboration%20(LBPMC)%20Group&rft.date=2017-07-01&rft.volume=77&rft.issue=11&rft.spage=1187&rft.epage=1197&rft.pages=1187-1197&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-017-0767-4&rft_dat=%3Cproquest_pubme%3E1973330974%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1973330974&rft_id=info:pmid/28573436&rfr_iscdi=true |